Abstract: The present invention is directed to a process for producing a master batch of pigment, comprising mixing a pigment having a high aspect ratio, embedded in a material increasing bulk density of the pigment, with a plastic so as to produce a dispersion of pigment and plastic.

Abstract: A PDE4 inhibiting compound is represented by

Abstract: The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein X is CH2, O or S. The compounds inhibit gamma secretase without affecting Notch signalling, and hence find use in the treatment or prevention of Alzheimer's disease.

Abstract: A substituted triazolopyridazine derivative, its use in cognition enhancement therapy, compositions containing it and processes for its manufacture.

Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

Abstract: To provide an ultraviolet absorbent having high UV shieldability, especially UV-A shieldability, high transparency and good dispersibility. An ultraviolet absorbent, which comprises a flaky substrate coated with ultra-fin zinc oxide particles having a mean particle size of not larger than 100 nm, and which is optionally treated with an organic silicone compound; and a method for producing the ultraviolet absorbent, which comprises calcining particles as coated with basic zinc carbonate in the presence of a complex-forming agent.

Abstract: The invention relates to a method for disubstituting carboxylic acid amides on the geminal carbonyl-C-atom using at least one grignard reagent in the presence of a metal alcoholate compound used as a catalyst and in the presence of another organometallic compound used as a co-catalyst.

Abstract: The present invention relates to fluoro-&agr;,&ohgr;-bis[(fluoroalkyl)fluorophosphorano)]alkanes, to a process for their preparation, and to their use as intermediates.

Abstract: Fluoroalkylphosphate salts of Formula I, described herein, are suitable for use, alone or in mixtures with, e.g., other salts, in electrolytes, primary batteries, secondary batteries, capacitors, supercapacitors or galvanic cells.

Abstract: A compound of formula I, or a salt or prodrug thereof: wherein: Z represents C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, aryl, C3-7 heterocycloalkyl, heteroaryl or di(C1-6)alkylamino, any of which groups may be optionally substituted; R1 represents an optionally substituted five-membered heteroaromatic ring selected from oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; or R1 represents an optionally substituted six-membered heteroaromatic ring selected from pyrazine, pyrimidine and pyridazine; and R2 represents cyano(C1-6)alkyl, hydroxy(C1-6)alkyl, C3-7 cycloalkyl(C1-6)alkyl, propargyl, C3-7 heterocycloalkylcarbonyl(C1-6)alkyl, aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted; its use in treating anxiety and pharmaceutical compositions comprising it; a subclass of compounds which are useful in enhancing cognition, such as Alzheimer's Disease, is also disclosed.

Abstract: The present invention relates to 2,6-di-tert-butylphenols of the formula I in which R, A1 A2, Z1, Z2 m and n are as defined herein, and their use as stabilizers or antioxidants.

Abstract: Amine salts of 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid are potent antagonists of the integrin &agr;v&bgr;3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts. Also disclosed are 3(R)- and 3(S)-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid in the form of a zwitterion trihydrate.

Abstract: Acetylene derivatives of the formula I in which R, A1, A2, Z1, Z2, Z3, L1, L2, L3, Y, m and n are as defined herein are suitable as components of liquid-crystalline media.

Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters, N-oxides and hydrates thereof are disclosed. Pharmaceutical compositions and methods of use are also included. The compounds are active against the caspase-3 enzyme, and thus are useful to treat fin caspase-3 mediated diseases and conditions.

Abstract: The invention relates to a plastic part having lustrous pigments and filler particles. Moldings of this plastic part exhibit a pronounced glitter effect.

Abstract: Liquid-crystalline media comprising one or more compounds of formula A 1

Abstract: Described are dialkyne compounds of the formula I 1

Abstract: The invention relates to supertwist liquid-crystal displays (STN-LCDs) having short switching times and good steepnesses and angle dependencies, and to the novel nematic liquid-crystal mixtures used therein, which comprise compounds having a 3,4,5-trifluorophenyl group together with compounds of formula I wherein R3 is an alkenyl group with 2 to 7 C atoms, R4 is an optionally fluorinated alkyl, alkoxy, alkenyl or alkenyloxy group with 1 to 12 C atoms, wherein one or two non-adjacent CH2 groups can be replaced by —O—, —CH═CH—, —CO—, —OCO— or —COO— in such a manner that O atoms are not directly adjacent to one another, or, in case m=1, R4 can also be Q—Y, Q is CF2, OCF2, CFH, OCFH or a single bond, Y is F or Cl, L1 and L2 are each independently H or F, and m is 0 or 1.

Abstract: The invention relates to a method of preparing lithium complex salts and their intermediaries and to the use of these in electrolytes.

Abstract: Compounds described by the chemical structural formula or a pharmaceutically acceptable salt thereof, are useful in the treatment of pain, migraine, depression, anxiety, schizophrenia, Parkinson's disease, stroke, and in the treatment of neuropathies including postherpetic neuralgia, central pain from spinal cord injury, and phantom limb pain.